Certara Launches DIDB® Concomitant Meds Navigator, Extending Leadership in Drug Interaction Science
Meet DIDB Concomitant Meds Navigator—an evidence-based tool to identify contraindicated or monitored co-medications and manage…
CertaraSeptember 22, 2025
Drug Interaction Database (DIDB ®)
Optimize DDI knowledge throughout drug development
CertaraSeptember 19, 2025
Certara Launches Libra™: AI-Powered Drug-Induced Liver Injury Prediction Tool
RADNOR, Pa. – September 17, 2025 – Certara, Inc. (Nasdaq: CERT), a global leader in…
CertaraSeptember 17, 2025
Replacing traditional TQT studies with model-based concentration-qtc (C-qtc) analysis for cardiovascular safety in drug development
Learn how our experts use concentration-QTc (C-QTc) analysis to replace costly TQT studies, streamline QT…
CertaraAugust 6, 2025
De-risking DDI Management during Clinical Trials: Introducing DIDB’s Concomitant Meds Navigator
Watch the on-demand presentation covering how the DIDB® Concomitant Meds Navigator empowers clinical development teams…
CertaraAugust 5, 2025
Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling
Certara announces that EMA has formally qualified the Simcyp® Simulator for use in regulatory submissions…
CertaraAugust 4, 2025
What are the most common in vitro drug-drug interaction study gaps?
Certara drug interaction science experts share data and experimental design gaps commonly found in in…
CertaraJune 9, 2025
